Paraneoplastic myasthenia gravis: Immunological and clinical aspects

European Journal of Neurology

Volumn 15, Issue 10, 2008, Pages 1029-1033

  Skeie, G O ^a   Romi, F ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Myasthenia gravis; Paraneoplasia; Thymoma

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CONNECTIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECEPTOR ANTIBODY; RITUXIMAB; RYANODINE RECEPTOR; TACROLIMUS;

CANCER SURGERY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; PARANEOPLASTIC SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SYMPTOM; THYMECTOMY; THYMOMA;

AGE OF ONSET; ATROPHY; AUTOANTIBODIES; AUTOANTIGENS; COMBINED MODALITY THERAPY; HUMANS; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MUSCLE PROTEINS; MYASTHENIA GRAVIS; NERVE TISSUE PROTEINS; PARANEOPLASTIC POLYNEUROPATHY; PLASMAPHERESIS; PROGNOSIS; PROTEIN KINASES; RECEPTORS, CHOLINERGIC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; THYMECTOMY; THYMOMA; THYMUS GLAND; THYMUS NEOPLASMS;

EID: 51349128258     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02242.x     Document Type: Review

References (36)

1. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001 357 : 2122 2128.
2. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. National Review of Cancer 2004 4 : 36 44.
3. Marx A, Kirchner T, Hoppe F, et al. Proteins with epitopes of the acetylcholine receptor in epithelial cell cultures of thymomas in myasthenia gravis. American Journal of Pathology 1989 134 : 865 877.
4. Romi F, Bo L, Skeie GO, Myking A, Aarli JA, Gilhus NE. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. Journal of Neuroimmunology 2002 128 : 82 89.
5. Skeie GO, Bentsen PT, Freiburg A, Aarli JA, Gilhus NE. Cell-mediated immune response against titin in myasthenia gravis: evidence for the involvement of Th1 and Th2 cells. Scandinavian Journal of Immunology 1998 47 : 76 81.
6. Gilhus NE, Willcox N, Harcourt G, et al. Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells. Journal of Neuroimmunology 1995 56 : 65 76.
7. Scarpino S, Di Napoli A, Stoppacciaro A, et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clinical Experimental Immunology 2007 149 : 504 512.
8. Strobel P, Rosenwald A, Beyersdorf N, et al. Selective loss of regulatory T cells in thymomas. Annals of Neurology 2004 56 : 901 904.
9. Chuang WY, Ströbel P, Gold R, et al. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Annals of Neurology 2005 58 : 644 648.
10. Amdahl C, Alseth EH, Gilhus NE, Nakkestad HL, Skeie GO. Polygenic disease associations in thymomatous myasthenia gravis. Archives of Neurology 2007 64 : 1729 1733.
11. Monstad SE, Drivsholm L, Skeie GO, Aarseth JH, Vedeler CA. CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunology and Immunothearpy 2008 57 : 227 232.
12. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clinical Cancer Research 2004 10 : 7270 7275.
13. Shiono H, Wong YL, Matthews I, et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. International Immunology 2003 15 : 903 913.
14. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 2001 57 : 1579 1582.
15. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle and Nerve 2000 23 : 453 477.
16. Aarli JA, Stefansson K, Marton LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clinical Experimental Immunology 1990 82 : 284 288.
17. Granzier H, Labeit S. Structure-function relations of the giant elastic protein titin in striated and smooth muscle cells. Muscle and Nerve 2007 36 : 740 755.
18. Somnier FE, Skeie GO, Aarli JA, Trojaborg W. EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis. European Journal of Neurology 1999 6 : 555 563.
19. Luckman SP, Skeie GO, Helgeland G, Gilhus NE. Morphological effects of myasthenia gravis patient sera on human muscle cells. Muscle and Nerve 2006 33 : 93 103.
20. Zorzato F, Fujii J, Otsu K, et al. Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. Journal of Biological Chemistry 1990 265 : 2244 2256.
21. Pagala MK, Nandakumar NV, Venkatachari SA, Ravindran K, Namba T, Grob D. Responses of intercostal muscle biopsies from normal subjects and patients with myasthenia gravis. Muscle and Nerve 1990 13 : 1012 1022.
22. Iwasa K, Komai K, Takamori M. Spontaneous thymoma rat as a model for myasthenic weakness caused by anti-ryanodine receptor antibodies. Muscle and Nerve 1998 21 : 1655 1660.
23. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurologica Scandinavica 2005 111 : 134 141.
24. Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. Journal of Neurology 2000 247 : 369 375.
25. Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. European Journal of Neurology 2007 14 : 617 620.
26. Liu W, Tong T, Ji Z, Zhang Z. Long-term prognostic analysis of thymectomized patients with myasthenia gravis. Chinese Medical Journal 2002 115 : 235 237.
27. Romi F, Gilhus NE, Varhaug JE, Myking A, Aarli JA. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. European Journal of Neurology 2003 10 : 701 706.
28. Oosterhuis HJGH, Limburg PC, Hummel-Tappel E. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. Journal of the Neurological Sciences 1983 58 : 371 385.
29. Pascuzzi RM. The edrophonium test. Seminars in Neurology 2003 23 : 83 88.
30. Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction disorders. American Journal of Physical Medicine and Rehabilitation 2005 84 : 627 638.
31. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database System Review 2002 4 : CD002275.
32. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database System Review 2003 2 : CD002277.
33. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003 61 : 1652 1661.
34. Venuta F, Rendina EA, De Giacomo T, et al. Thymectomy for myasthenia gravis: a 27-year experience. European Journal of Cardio-Thoracic Surgery 1999 15 : 621 625.
35. Takamori M, Motomura M, Kawaguchi N, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004 62 : 1894 1896.
36. Konishi T, Yoshiyama Y, Takamori M, et al. Clinical study of FK506 in patients with myasthenia gravis. Muscle and Nerve 2003 28 : 570 574.